Glucoregulation in type 2 diabetes: The lower the better? Glycosylated HbA1c of 6.5% seems to be the limit

European Journal of Internal Medicine

Volumn 20, Issue 3, 2009, Pages 232-235

  Jazet, I M ^a   Meinders, A E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ACCORD; ADVANCE; Cardiovascular risk; HbA1c; Tight glucoregulatin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; INSULIN; METFORMIN;

ALBUMINURIA; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL STUDY; COGNITION; DEATH; DIABETIC NEPHROPATHY; DISEASE DURATION; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INTENSIVE CARE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; QUALITY OF LIFE; REVIEW; STROKE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; REFERENCE STANDARDS; RISK FACTORS;

EID: 67349127630     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2008.08.002     Document Type: Review

References (25)

1. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 2 (1993) 434-444
2. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 4 (1998) 229-234
3. Sheetz M.J., and King G.L. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288 20 (2002) 2579-2588
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 9131 (1998) 837-853
5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329 14 (1993) 977-986
6. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 25 (2005) 2643-2653
7. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 7258 (2000) 405-412
8. Selvin E., Marinopoulos S., Berkenblit G., Rami T., Brancati F.L., Powe N.R., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141 6 (2004) 421-431
9. Gerstein H.C., Pogue J., Mann J.F., Lonn E., Dagenais G.R., McQueen M., et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 48 9 (2005) 1749-1755
10. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 9131 (1998) 854-865
11. Kearney P.M., Blackwell L., Collins R., Keech A., Simes J., Peto R., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 9607 (2008) 117-125
12. Standards of medical care in diabetes-2008. Diabetes Care 31 Suppl 1 (2008) S12-S54
13. Effects of intensive glucose lowering in type 2 diabetes. The Action to Control Cardiovascular Risk in Diabetes Study Group. 358, 2545-59. 2008.
14. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The ADVANCE Collaborative Group. 358, 2560-72. 2008.
15. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 13 (2004) 1296-1305
16. Gerstein H.C., Mann J.F., Yi Q., Zinman B., Dinneen S.F., Hoogwerf B., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286 4 (2001) 421-426
17. Kirkman M.S., McCarren M., Shah J., Duckworth W., and Abraira C. The association between metabolic control and prevalent macrovascular disease in type 2 diabetes: the VA Cooperative Study in diabetes. J Diabetes Complicat 20 2 (2006) 75-80
18. Despres J.P., Lamarche B., Mauriege P., Cantin B., Dagenais G.R., Moorjani S., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334 15 (1996) 952-957
19. Muis M.J., Bots M.L., Bilo H.J., Hoogma R.P., Hoekstra J.B., Grobbee D.E., et al. High cumulative insulin exposure: a risk factor of atherosclerosis in type 1 diabetes?. Atherosclerosis 181 1 (2005) 185-192
20. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 24 (2007) 2457-2471
21. Pan N.H., Lee T.M., Lin M.S., Huang C.L., and Chang N.C. Association of gliclazide and left ventricular mass in type 2 diabetic patients. Diabetes Res Clin Pract 74 2 (2006) 121-128
22. Fava D., Cassone-Faldetta M., Laurenti O., De L.O., Ghiselli A., and De M.G. Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in type 2 diabetes. Diabet Med 19 9 (2002) 752-757
23. Krumholz H.M., and Lee T.H. Redefining quality-implications of recent clinical trials. N Engl J Med 358 24 (2008) 2537-2539
24. Gaede P., Lund-Andersen H., Parving H.H., and Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 6 (2008) 580-591
25. Saydah S.H., Fradkin J., and Cowie C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291 3 (2004) 335-342